|
|
|
시장보고서
|
Abstract
This report analyzes the worldwide markets for Prescription Drugs in US$
Billion by the following therapeutic class -Oncologics/ Cancer Drugs, Lipid
Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics,
Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics,
Autoimmune Agents, and Others. The report provides separate comprehensive
analytics for the US Canada, Japan, Europe, Asia-Pacific, Latin America, and
Rest of World. Annual forecasts are provided for each region for the period
2006 through 2015. A five-year historic analysis is also provided for these
markets. The report profiles 292 companies including many key and niche
players worldwide such as Abbott Laboratories, Allergan, Inc., Amgen, Inc.,
AstraZeneca, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim Group, Dr.
Reddy' s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd.,
Genentech, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Inc., Merck & Co.
Inc., Merck Serono International S.A., Mylan, Inc., Novartis AG, Pfizer, Inc.,
Ranbaxy Laboratories Limited, Sanofi-Aventis SA, Sanofi Pasteur, Takeda
Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Watson
Pharmaceuticals, Inc., and Wyeth. Market data and analytics are derived from
primary and secondary research. Company profiles are mostly extracted from URL
research and reported select online sources.
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definition and Scope of Study
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW & OUTLOOK
- Pharma Industry Hit by Economic Downturn
- Table 1: Worldwide Prescription Drugs Sales: 2006-2015 (includes
corresponding Graph/Chart)
- The Regional Impact
- Emerging Markets to Drive Growth
- Biotechnology
- Biotech Bankruptcies Rife in the Current Economic Downturn
- Economic Downturn Takes Toll on R&D
- Outsourcing - A Mixed Bag
- Generics - The Bright Spot
- Table 2: Increasing Share of Generics in the Global Pharmaceutical Market:
1995-2005 (In %) (includes corresponding Graph/Chart)
- Table 3: Generics Share in Select Markets Worldwide - United States,
Germany, UK, Spain, Japan, Italy, France, Finland, Denmark, The Netherlands,
Norway, and Ireland (includes corresponding Graph/Chart)
- Patent Expiries of Major Drugs: 2009-2012
- Patient Spending
- Operational Restructuring
- Rising R&D Costs Call for Improved Efficiency
- Concerns Over Drug Safety and Side Effects Impede Sales
- Policy Issues Threaten Innovation
- Regulatory Glitches and High Costs Hinder Biogeneric Growth
- Opportunities Outside Drug Development
- Going Forward in Forward Integration
- Forward Integration into Diagnostics
- Opportunities in Healthcare
- Down the Distribution Chain
2. LEADING PHARMA COMPANIES AND DRUGS WORLDWIDE
- Pfizer Reigns Supreme...
- Table 4: Leading Global Pharmaceutical Companies Worldwide by Sales (2008,
2007, and 2006) - Pfizer, GlaxoSmithKline, Novartis, Sanofi-Aventis,
AstraZeneca, Roche, Johnson & Johnson, Merck & Co., Abbott and Eli
Lilly - in US$ Billion (includes corresponding Graph/Chart)
- Leading Prescription Drugs Worldwide - Lipitor Leads the Way
- Table 5: Leading Prescription Drugs Worldwide by Sales (2008, 2007, and
2006)- Lipitor, Plavix, Nexium, Seretide, Enbrel, Seroquel, Zyprexa, Remicade,
Singulair and Levonox in US$ Billion (includes corresponding Graph/Chart)
- Oncology Tops Therapeutic Classes
- Table 6: Leading Therapeutic Classes Worldwide by Sales (2008, 2007, and
2006)- Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump
Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II
Antagonists, Anti-Epileptics, Autoimmune Agents and Others in US$ Billion
(includes corresponding Graph/Chart)
3. THERAPEUTIC DRUG CLASSES
- Cholesterol Reducers
- Statins Lead the Way
- Emerging Leaders
- Table 7: Leading Cholesterol Reducing Drugs Worldwide: Sales for the years
2004 through 2008 for Lipitor, Crestor and Vytorin (in US$ Billion) (includes
corresponding Graph/Chart)
- Lack of Product Differentiation Mars Prospects
- Zocor - The First Statin to Switch to OTC
- Patent Expiries of Leading Cholesterol Reducers: 2009 and Beyond
- Oncologics
- Oncologics/ Cancer Drugs - Largest Therapeutic Class
- High Unmet Needs to Drive Growth
- Biologics to Reign Supreme
- Leading Drugs
- Leading Players
- Novel Therapies
- Respiratory Drugs
- Leading Brands and Players
- Table 8: Leading Asthma Drugs Worldwide - Value Sales for the Years
2004-2008 for Seretide, Singulair, Symbicort and Pulmicort (in US$ Billion)
(includes corresponding Graph/Chart)
- Table 9: Select COPD and Allergic Rhinitis Drugs Worldwide: Value Sales
for the Years 2006-2008 for Spiriva, Nasonex and Zyrtec (In US$ Billion)
(includes corresponding Graph/Chart)
- Patent Expiries of Leading Respiratory Drugs: 2008 and Beyond
- Antipsychotics
- Leading Schizophrenia Drugs
- Side Effects of Antipsychotics - A Major Issue
- Patent Expiries
- Patent Expiries of Leading Anti-Psychotic Drugs
- Zyprexa Continues to Lose Market Share
- Risperdal Sales to Plunge, Following its Patent Expiry
- Generics - Yet to Make a Mark in Antipsychotics
- Increasing Use of Antipsychotics in Children Raises Concerns
- Proton Pump Inhibitors
- Patent Expiries of Leading Proton Pump Inhibitors: 2008 and Beyond
- Table 10: Leading Proton Pump Inhibitors Worldwide - Value Sales for the
Years 2004 through 2006 (US$ Billion) - Nexium, Prevacid/Takepron,
Protronix/Pantazol and AcipHex/Pariet (includes corresponding Graph/Chart)
- Antidepressants
- Patent Expiries of Leading Antidepressant Drugs Worldwide: 2005-2015
- Erythropoietins
- Competitive Landscape in the Global Erythropoietin Market
- Leading Erythropoietin Drugs
- Table 11: Leading Erythropoietin Drugs Worldwide - Annual Revenues for the
Years 2004 through 2007 in US$ Billion for Aranesp, Procrit/Eprex, Epogen and
NeoRecormon (includes corresponding Graph/Chart)
- New and Pipeline Products
- Biogenerics Pose Imminent Threat
- Anti-Arthritics
- Table 12: Leading Anti-arthritic Drugs Worldwide - Value Sales for Years
2006 through 2008 in US$ Billion - Enbrel, Remicade, Rituxan and Humira
(includes corresponding Graph/Chart)
- Anti-Epileptics
- Disease Statistics
- Available Drugs
- Generics to Take the Lead in Anti-Epileptic Market
- Table 13: Leading Anti-Epileptic Drugs Worldwide: Value Sales for years
2005 through 2007 in US$ Billion for Topamax, Lamictal, Depakote and Keppra
(includes corresponding Graph/Chart)
- Patent Expiries of Leading Anti-Epileptic Drugs
- New Launches
- Pipeline Drugs Bode Brighter Prospects
- Pipeline Drugs in Antiepileptics
- Calcium Channel Blockers
- Antidiabetics
- Table 14: Leading Anti-diabetic Drug Sales Worldwide: Value Sales for
Years 2005 through 2008 in US$ Billion for Actos, Lantus, Avandia Franchise,
Januivia and Byetta (includes corresponding Graph/Chart)
4. MARKET DYNAMICS
- Pharma M&A Activity in 2008
- Aggressive M&A Deals by Japanese Companies
- Patent Expiries
- Patent Expiries for 2008 and 2007
- New Product Approvals
- Table 15: New Drugs Approval from 2003-2008 (includes corresponding
Graph/Chart)
- Table 16: Biologics Approvals from 2003-2008 (includes corresponding
Graph/Chart)
- Table 17: Development of New Molecular Entities (Biological and Chemical)
by Various Region/Country: Percentage Share Breakdown for the Periods
1998-2002 & 2003-2007 (includes corresponding Graph/Chart)
- Table 18: Number of Compounds Under Development by Country/Region:
Percentage Breakdown for the year 2007 (includes corresponding Graph/Chart)
- New Molecular Entities (NMEs) Approved by FDA in 2008
- New Biological Entities Approved by FDA in 2008
- Research and Development
- Table 19: R&D Investments by Pharmaceutical Sector in US and Europe:
2004-2007 (includes corresponding Graph/Chart)
- Cost Pressures
- R&D Productivity Slides Despite Increasing Investments
- Aging Population Drives Demand
- Table 20: World Demographic Trends: People Over 65 as a Percentage of
Total Population by Geographic Region- US, Canada, Japan, Europe,
Asia-Pacific, and Latin America for years 2000, 2008, 2010, and 2020 (includes
corresponding Graph/Chart)
5. PRESCRIPTION PHARMACEUTICALS - AN OVERVIEW
- Biologics
- Evolution Of The Global Pharmaceutical Industry
- Drug Development Process - FDA Perspective
- Stages of Drug Development Process
- Drug Discovery
- Pre-Clinical Testing
- Clinical Trials
- Phase I Clinical Trial
- Phase II Clinical Trial
- Phase III Clinical Trial
- New Drug Application
- FDA Review
- Phase IV Clinical Trials
- FDA' s Drug Safety Review - The Global Standard
6. SELECT THERAPEUTIC CLASSES
- Anti-arthritics
- COX-2 Inhibitors
- Antipsychotic Drugs
- Anti-Ulcerants
- Codeine & Combinations
- Combination Drugs
- Anti-Depressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Noradrenaline Re-Uptake Inhibitors (SNRIs)
- Serotonin Modulators (5-HT2 blockers)
- Dopamine-norepinephrine Reuptake Inhibitors
- Monoamine Oxidase Inhibitors (MAOIs)
- Erythropoietin
- Proton Pump Inhibitors
- Seizure Disorder Drugs
- Antihistamines
- Calcium Channel Blockers
- Cholesterol Reducers
7. MARKETING AND PROMOTIONS
- Table 21: Promotional Spending by Major Pharma Companies (2006 and 2007)
in US$ Million - Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Sanofi-Aventis,
Novartis, Eli Lilly, Schering-Plough, Johnson & Johnson, and Bristol Myers
Squibb (includes corresponding Graph/Chart)
- Table 22: Promotional Spending through Professional Detailing by Major
Pharma Companies (2006 and 2007) in US$ Million - Pfizer, GlaxoSmithKline,
Merck, AstraZeneca, Novartis, Sanofi-Aventis, Eli Lilly, Johnson &
Johnson, Schering-Plough and Wyeth (includes corresponding Graph/Chart)
- Table 23: Direct-To-Consumer Promotional Spending By Major Pharma
Companies (2006 and 2007) in US$ Million - Pfizer, GlaxoSmithKline, Merck,
Bristol Myers Squibb, Sepracor, AstraZeneca, Schering-Plough, Sanofi-Aventis,
Boehringer Ingelheim and Eli Lilly (includes corresponding Graph/Chart)
- Table 24: E-Promotional Spending by Major Pharma Companies (2006 and 2007)
in US$ Million - Merck, GlaxoSmithKline, Johnson & Johnson, Pfizer, Shire,
Eli Lilly, Schering-Plough, AstraZeneca and Sanofi- Aventis (includes
corresponding Graph/Chart)
8. RECENT INDUSTRY ACTIVITY
- Merck & Co. and Schering-Plough to Merge
- Pfizer to Acquire Wyeth
- CSL and Talecris Biotherapeutics to Withdraw Merger Agreement
- AstraZeneca Partners with Merck to Analyze a New Combination of Anticancer
Regimen
- Sun Pharmaceutical Acquires Chattem
- Novartis Acquires 25% Stake in Alcon
- Takeda Acquires Millenium Pharmaceuticals
- Teva Acquires Barr
- Invitrogen and Applied Biosystems Merge
- Eli Lilly Takes Over ImClone Systems
- Daiichi- Sankyo Acquires Controlling Stake in Ranbaxy
- Fresenius Acquires APP Pharmaceuticals
- TPG Acquires 50% Stake in SIA International
- GSK Acquires Sirtris
- Shire Aquires Controlling Interest in Jerini
- Boehringer Ingelheim to Purchase Actimis Pharmaceuticals
- Sanofi Pasteur Acquires Acambis
- Sanofi-Aventis Acquires Symbion
- Nordic and Avista Acquires ConvaTec
- King Pharmaceuticals Acquires Alpharma
- Shionogi Acquires Sciele
- Ranbaxy Inks Indian Marketing License for GLIADEL(r) with BioPro
- Tibotec Gains EC Approval for PREZISTA(r)' s Extended Indication
- GSK and Neptunus to Set up Joint Venture for Developing Flu Vaccines
- AstraZeneca Obtains TRO for Generic Pulmicort Respules
- Solvay Pharmaceuticals Enters Into a License Deal with Depomed
- AstraZeneca Enters into an Agreement with Par Pharmaceutical
- BioReliance and Provecs Enter into Agreement
- Cornerstone BioPharma and Critical Therapeutics Merge to Form Cornerstone
Therapeutics
- GSK to Acquire Genelabs
- Lpath and Merck Serono Forge Partnership
- Allergan and Spectrum Ink Collaboration Deal for Bladder Cancer Drug
- EMD Signs Licensing and Collaboration Deal with Theratechnologies
- Medimetriks Receives License for Prescription Brands from Perrigo
- Forest Partners with Phenomix for Developing Diabetic Drug
- GSK Biologicals and AFFiRiS Sign Collaboration Agreement
- Sanofi-Aventis Strengthens R&D Operations in the Chinese Market
- UCB and Pfizer Establish Cyclofluidic
- Valeant Pharmaceuticals Completes Coria Laboratories Acquisition
- MedImmune Inks Agreement with Omninvest over Reverse Genetic Technology
- Avidas Secures North American Rights of Crown' s Dermatology Products
- Lilly Acquires Two Compounds for Early-Stage Tuberculosis Drug Pipeline
- Eli Lilly and Deciphera Enter into Collaboration and Licensing Deal
- Roche, GlycArt and Genentech Sign Collaboration Agreement
- Cardinal Health Plans to Spin-Off Medical and Clinical Products Businesses
- Sanofi Pasteur Holding Acquires Acambis
- Eisai Plans NDA Submission for Insomnia Drug
- GlaxoSmithKline Enter into Strategic Alliance with Cellzome
- Ablynx and Merck Serono Sign Nanobodies(r) Agreement
- GlaxoSmithKline and Valeant Enter into Collaborative Agreement
- Noven Enters Supply and License Agreements with P&G Pharmaceuticals
- Eli Lilly Acquires SGX Pharmaceuticals
- SymBio Pharmaceuticals Enters into a License Agreement with Eisai
- Roche Sells Four Pharmaceutical Products to Meda AB
- AstraZeneca Joins Hands with Abbott for Co-Promotion of Crestor
- Gilead Sciences Inks Atripla(r), HIV Drug Distribution Deal with Merck
- Eisai China Enters into Licensing Deal with Health Vision
- GSK and Harvard Stem Cell Institute Team Up for Drug Discovery
- Teva Acquires Bentley Pharmaceuticals
- Roche to Acquire ARIUS Research
- GlaxoSmithKline and Actelion Collaborate
- GSK Enters into Product Disinvestment Agreement with Aspen
- Lupin Forges Marketing Alliance with ASCEND for Suprax(r) Tablets
- Merck Serono Inks Multiple Sclerosis Drug-Development Deal with Bionomics
- European Commission Approves Kuvan(r) of Merck Serono
- GSK Collaborates with Mpex for Developing Anti-Bacterial Drugs
- Eli Lilly Announces Development & Licensing Agreement with TransPharma
- Mylan Obtains Exclusive Marketing Rights for Glatiramer from NATCO
- Sepracor Acquires Oryx Pharmaceuticals
- Mylan Takes Over Merck' s Outstanding Generics Operations
- Gilead Acquires Cicletanine Business from Navitas
- King Pharmaceuticals to License Third Opioid Analgesic Product
- BioPhausia Acquires Prescription Pharmaceutical Offerings from AstraZeneca
- Ranbaxy Enters into Strategic Product Development Agreement with Merck
- EUSA Pharma Acquires Cytogen Corporation
- Dr. Reddy' s Announces Two Major Acquisitions
- EUSA Divests Stake in Antibody Research and Oncology Product to IDD
- Sanofi Pasteur Delivers H5N1 Bulk Vaccine Antigen to HHS
- Ranbaxy Inks Strategic Business Alliance with Orchid
- Pfizer Settles Patent Litigation for Lipitor with Ranbaxy
- GSK Enters into Collaboration with Regulus Therapeutics
- Janssen to Launch J&J Group' s New Drugs in Japan
- Roche Alliance Partner Obtains Approval for Actemra in Japan
- Abbott Receives Japanese Approval for Rheumatoid Arthritis Drug, HUMIRA(r)
- Dr. Reddy' s Completes Acquisition of Jet Generici Srl
- Eli Lilly, Transition Therapeutics Announce Licensing and Partnership
Agreement
- Dr. Reddy' s and 7TM Sign Drug Discovery Agreement for Selected Drug Targets
- Endo Pharmaceuticals Obtains US Rights for Novartis' Voltaren(r) Gel
- Pfizer to Take Over Serenex
- Sanofi-aventis, Amyris, iOWH Sign Semisynthetic Artemisinin Development
Deal
- AstraZeneca Files sNDA for Depressive Disorder Drug, Seroquel XR(tm)
- Forest, Mylan Amend Bystolic Agreement
- Fujifilm to Acquire Stake in Toyama Chemicals
- Graceway Takes Over Estrasorb
- Ranbaxy Announces De-Merger of New-Drug Discovery Research Unit
- AstraZeneca Inks Deal with Nomura Phase4 Ventures to Form Albireo
- Cellegy to Merge with Adamis Pharmaceuticals
- Mylan Reaches Accord with Novartis for Femara(r)' s Generic Product
- Dyax Signs Licensing and Development Agreements with Sanofi-aventis
- AstraZeneca Files for EU Approval of Seroquel XR(tm)
- MedImmune Files Biologics License Application for motavizumab to FDA
- Farmavita, Belupo Sign Contract for Strategic Merger
- Pfizer Japan Secures Production and Marketing Approval for Champix(r)
- Eisai Enters into License Agreement with Abbott
- Eisai Takes Over MGI Pharma
- KV Pharmaceutical to Acquire Rights for Gestiva(tm) from Hologic
- Forest and Novexel Enter into Licensing Agreement
- Dr. Reddy' s Enters Settlement Agreement with Novartis for Exelon(r)
- Taisho and Pfizer Sign Agreement for TS-032
- Crucell Enters into Agreement with Sanofi Pasteur
- EMEA Approves Second Biogeneric EPO, Retacrit
- Endo Pharmaceuticals Licenses AZ-003 from Alexza
- Schering-Plough and Centocor Modify Existing Distribution Agreement
- GSK and Santaris Pharma Collaborate in RNA Antagonists Research
- GSK Acquires Reliant Pharmaceuticals
- Eisai and Minophagen Ink In-Licensing Agreement for Liver Disease/
Allergic Disease Agents
- Bristol-Myers, Gilead Extend Agreement to Commercialize ATRIPLA(r) in
Europe
- GSK and OncoMed Team Up for Antibody Therapeutics for Cancer Stem Cell
Research
- GSK Allies with Galapagos for Antiviral and Antibacterial Development
- Eisai and BioArctic Ink Licensing Deal for BAN2401
- Biogen and Neurimmune Join Hands to Develop Drugs for Alzheimer' s Disease
- Sanofi-aventis Institutes GDC, Pharmaceutical Development Center in India
- AstraZeneca Obtains Pediatric Exclusivity for ARIMIDEX(r) from FDA
- Covance to Build High-Tech Drug Development Facility
- Schering-Plough Takes Over Organon BioSciences
- Takeda Launches Takeda San Francisco for Therapeutic Antibody Research
- GSK to Disinvest Lotronex(r)
- Gilead and LGLS Enter Global License Deal for Fibrotic Diseases Therapy
- Watson Acquires Andrx
- EPFL and Merck Serono Enter into Agreement
- Acura and King R&D Sign Licensing Agreement for Opioid Analgesic
Products
- Eli Lilly Inks License Agreement with Glenmark Pharmaceuticals
- Wockhardt Takes Over Morton Grove Pharmaceuticals
- GSK Enters into Collaboration with Tolerx for Development of Novel
Therapies
- Chugai Pharmaceuticals Obtains Approval for Tarceva in Japan
- Eli Lilly Announces Strategic Alliance with MacroGenics
- BMS, ImClone, Merck Serono Sign Erbitux(r) Agreement
- Wockhardt to Market Gnosis' SAMe in India
- Alpharma Grants US License for Ketoprofen in Transfersome(r) Gel to IDEA
- Forest and Daiichi Sankyo Sign Contract to Co-Promote AZOR(tm)
- Synta and GSK Sign Oncology Molecule Development Collaboration
- Cyclacel to Take Over ALIGN Pharmaceuticals and ALIGN Holdings
- GSK Inks Antiviral and Antibacterial Drug Development Deal with Anacor
- AMRI Enters into Research Collaboration with Cystic Fibrosis Foundation
- Mylan Takes over Merck Generics
- Kissei and Eisai Ink Licensing Deal for Glufast(r) Tablets
- AMRI Inaugurates New Research Unit in Hyderabad
- Eisai Inks Co-Promotion Deal with Salix for COLAZAL(r) Capsules
- Kowa and Teva to Establish Joint Venture Generic Drug Firm in Japan
- Nisshin Seifun Pulls Out of Joint Venture Nisshin Kyorin Pharmaceutical
- Chugai and Teijin Sign Agreement for Co-Development of Anti-Diabetic Drug
- MedImmune Inks Licensing Agreement with Novartis over Reverse Genetic
Technology
- EUSA Acquires Assets of Innocoll
- Noven Enters Supply and License Agreements with P&G Pharmaceuticals
- Parion and Gilead Ink Deal to Develop Drug Candidates for Pulmonary Disease
- Noven Pharmaceuticals Acquires JDS Pharmaceuticals
- HHS Places an Order with GSK for Bulk H5N1 Antigen
- Synthon Completes Laboratorios Rider Acquisition
- Targacept Forges Partnership with GSK
- Dong Wha Signs Alliance with P&G Pharma to Develop Treatment Molecules
for Osteoporosis
- Barr and Gedeon Richter Sign Pact over Generic Version of LAMISIL(r)
- Santarus and Victory Pharma Enter Into Co-Promotion Agreement
- AMRI Enters into Collaboration for Research with Achaogen
- SCI Collaborates with High Q Foundation for Research on Huntington' s
Disease
- MonoSol Rx Signs License Agreement with Strativa Pharmaceuticals
- Eli Lilly to Launch Public-Private Partnership for Drug Research in
Tuberculosis
- Merck Serono and Bristol-Myers Squibb Ink Latin American Distribution Deal
- Strides Arcolab to Take Over Bio-Fermentation Facility in Italy
- Amgen to Take Over Alantos Pharmaceuticals
- GlaxoSmithKline Establishes R&D Center in China
- Wockhardt Acquires Negma Laboratories
- Eisai Inks Exclusive Agreement with Solstice over NeuroBloc(r)
- Ranbaxy to Acquire Be-Tabs Pharmaceuticals
- Pfizer Obtains Health Canada Approval for LIPITOR in Reducing Myocardial
Infarction
- GSK Allies with Wellcome to Develop Antibacterials for Hospital-Contracted
Infections
- Bristol-Myers and Pfizer Ink Development and Commercialization Agreements
- Cytos Biotechnology Grants Novartis with Global License for NicQb
- Swiss Federal Register Adds ACOMPLIA(r) to Reimbursement List
- Wockhardt to Introduce Syrio Pharma' s B-Lift Product Range in India
- Eisai Acquires Morphotex
- Ranbaxy Obtains Approval for RAN(tm) Cefprozil Formulations in Canada
- Roche Partners with Transgene to Focus on Therapeutic Vaccine Program
- Cardinal Health Divests Pharmaceutical Technologies and Services Segment
to Blackstone Group
- Roche to Acquire BioVeris Corporation
- Eli Lilly Acquires Hypnion
- Roche Takes Over THP, Broadens Antibody Research Facility
- Oxford BioMedica Enters into Development Deal with Sanofi-Aventis for
TroVax(r)
- Iroko Pharmaceuticals Acquires Rights to Indocin(r) and Aldomet(r) Products
- Asahi Kasei Inks Licensing Agreement with Eisai Korea over Vasodilator
Eril(r)
- Merck Obtains EU Approval for JANUVIA(tm) Type 2 Diabetes Drug
- Wockhardt Obtains FDA Approval for a Painkiller in the US
- Ortho-McNeil Obtains Pediatric Extension for LEVAQUIN(r)
- GlaxoSmithKline Obtains FDA Approval for Tykerb(r)
- Terapia Ranbaxy Secures Marketing Approvals for 20 New Products
- Shionogi to Develop and Market BioCryst' s peramivir in Japan
- Abbott and Eisai Amend Co-Promotion Agreement over HUMIRA(r) in Korea and
Taiwan
- Salix Acquires US Rights to Merck' s Two Oral Suspension Products
- Takeda Expands Collaboration with XOMA in Potential Therapeutic Antibody
Programs
- GSK Commences Phase III Clinical Trials of Tykerb(r), a Post-Operative
Lapatinib
- Roche Grants Glaxo with Exclusive Licensing Rights to its ' Orlistat' Drug
- GSK and HGS Commence Phase III Trials of LymphoStat-B(r) in SLE
- GSK and Fabre-Kramer Ink Global Deal for Gepirone ER
- Ranbaxy Signs Agreement with Zenotech for Biosimilars' Global Launch
- Ranbaxy Inks Long-Term R&D Deal with GSK
- Amgen Inks Three-year Aranesp Supply Agreement with Fresenius
- AstraZeneca to Take Over Arrow Therapeutics
- Eli Lilly Acquires ICOS Corporation
- Pfizer Plans to Takeover BioRexis
- Solvay Inks Licensing Deal with Jazz Pharmaceuticals for LUVOX(r)
- Eisai' s ' Pariet(r), 10mg Tablets' Receive Clearance for New Indication in
Japan
- Eisai Receives EC Approval for Inovelon(r)
- Pfizer Receives Marketing Authorization for Sutent(r) in European Union
- GlaxoSmithKline Obtains Approval to Market Wellbutrin XR(r) in the
Netherlands
- Forest Laboratories Acquires US Biopharmaceutical Company, Cerexa
- Mylan Laboratories Acquires 51.5% in Matrix
- DUSA Enters into an Agreement with Daewoong Pharmaceutical
- Penwest and Endo Amend Existing Contract on Opana(r) ER Collaboration
- Eli Lilly Licenses Glucokinase Activator Program from OSI Pharmaceuticals
- Graceway Pharmaceuticals Acquires 3M Pharmaceuticals Business
- Ranbaxy Obtains FDA Approval for Atenolol Tablets
- Gilead Sciences Acquires Myogen
- Gilead Sciences Acquires Raylo Chemicals
9. FDA APPROVALS FOR 2009, 2008 AND 2007
10. A REVIEW OF SELECT PRODUCT INTRODUCTIONS IN THE PHARMA INDUSTRY
- Amgen Receives Approval for Nplate(R)...
- Takeda Wins FDA Marketing Approval for ULORIC...
- Novartis and MMV Launch Coartem(r) Dispersible
- Ipsen and Medicis Receives FDA Approval for Dysport...
- Centocor Receives FDA Approval for Simponi...
- Wyeth Receives FDA Approval for PRISTIQ(tm)...
- GSK Receives FDA Approval for Promacta(r)...
- Cephalon Receives FDA Approval for TREANDA...
- Adolor Receives FDA Approval For Entereg(R)...
- Lundbeck Introduces Xenazine* (Tetrabenazine) Tablets
- Eisai US Receives FDA Approval for Banzel(tm) (Rufinamide)
- Progenics Receives FDA Approval for RELISTOR...
- J&J Receives Approval for Anti-HIV Medication ' Intelence' ...
- Sandoz Launches Generic Fluoxetine Hydrochloride Capsules in US
- Sandoz Introduces Eplerenone Tablets
- Wockhardt Introduces Midazolam Injection in the US
- Dr. Reddy' s Announces Launch of Generic Version of Imitrex(r) Tablets
- Arbor Pharmaceuticals Debuts NEOTIC(tm) for Middle- Ear Infections
- Promius Pharma Introduces EpiCeram(r) Emulsion
- Sandoz Unveils Generic Variant of Imitrex(r) Injection
- Dr. Reddy' s Launches Redihaler(tm) and Combihale(tm)
- Wyeth Launches Antihemophilic Factor, XYNTHA(tm)
- Bayer Schering Releases YAZ(r)
- Mylan Introduces Nisoldipine ER Tablets in US
- Ranbaxy Launches Generic Omeprazole in US
- Ranbaxy Unveils Generic Equivalent of Amlodipine Tablets
- Teva Unveils Generic Equivalent of Lamictal(r) Tablets
- Eisai and Helsinn Healthcare Introduce ALOXI(r) Injection for Prevention
of PONV
- Janssen and Patriot Unveil Authorized Generic Equivalent for Risperdal(r)
- Watson Releases Generic Equivalent of MARINOL(r)
- Sandoz Introduces Generic Form of Altace(r)
- Abbott Introduces Aluvia(r) Tablet in South Africa
- Dr. Reddy' s Rolls-out Atocor-R
- Sandoz Unveils Generic Form of Maxipime(r)
- Tibotec Therapeutics Introduces New 600mg Dosage Strength for PREZISTA
- Ranbaxy Pioneers Launch of New Bio-Generic Recombinant Osteoporosis
Injection
- Sandoz Introduces Generic Variant of Antizol(r) Injection
- Sun Pharmaceuticals Introduces Injection of Amifostine
- Sandoz Re-Launches Generic Form of Bactocill(r) Injection
- Sandoz Introduces Generic Form of Cipro(r) Injection
- Merck Serono Introduces Cyanokit(r) in Japanese Market
- Ranbaxy Launches INERSAN Tablets in India and Nepal
- Sandoz Launches Omnitrope(tm) Pen 5 with Liquid Cartridge
- Endo Pharmaceuticals to Introduce OPANA(r) ER in Three Dosage Strengths
- Sandoz Releases Generic Form of Camptosar(r)
- Sun Pharmaceuticals Unveils Pantoprazole Sodium DR Tablets
- Dr. Reddy' s Introduces Supanac(r)
- Watson Announces Launch of Clarithromycin 500mg Extended-Release Tablets
- GSK Announces FDA approval of Altabax(tm)...
- Novartis' Tekturna HCT(r) Receives FDA Approval...
- GSK Receives FDA Approval for Tykerb(r)...
- Pfizer Receives FDA Approval for Selzentr...
- Ortho-McNeil Receives Approval for DORIBAX(tm)...
- Merck Receives Approval for Isentress(r) ...
- BMS Wins FDA Approval for IXEMPRA(tm)...
- Novartis' Tasigna(r) Receives FDA Approval...
- Mylan Receives FDA Approval for Bystolic...
- Roche' s Mircera Secures FDA Approval...
- Eisai Launches New Dose Formulations of Aricept(r) Tablets in Japan
- Chugai Launches Tarceva(r) Tablet in Japan
- Sandoz Introduces Generic Version of Elocon(r) Lotion
- Ranbaxy to Introduce Tamsulosin Hydrochloride Capsules in Canada
- Watson Unveils Tilia(tm) Fe
- Ranbaxy Obtains Health Canada Approval for Ran(r)- Lisinopril Oral Tablets
- Sandoz Releases Generic Form of Delestrogen(r) Injections
- Sanofi and UCB Roll Out XYZAL(r) in US
- Sandoz Expands Range of Generic Augmentin(r) Drugs
- Sandoz Releases Generic Variant of Biaxin(r) for Oral Suspension
- Sandoz Introduces Generic Form of Penlac(r) Topical Solution
- Teva Releases Famciclovir Tablets
- Ranbaxy Introduces Roliflo OD in India
- Sandoz Introduces Generic Form of Toprol Xl(r) 50Mg Extended Release Tablet
- Dr. Reddy' s Introduces Glimy MP1 and Glimy MP2
- Sandoz Launches Approved Generic Equivalent of Lamisil(r)
- Ranbaxy Introduces Pravastatin Sodium 80mg Tablets in the US
- AstraZeneca Announces the Availability of Symbicort(r) pMDI
- Chugai and Maruho Announce the Launch of Oxarol(r) Lotion
- Ajinomoto and Eisai Jointly Launch ' Actonel(r) 17.5mg Tablets'
- Sandoz Introduces Approved Generic Form of Lotrel(r)
- Dr. Reddy' s Launches UltravexTM
- Wockhardt Unveils Zolpidem Tablets in the US
- Dr. Reddy' s Introduces Reditux(tm)
- Dr. Reddy' s Secures Approval for Launching Zolpidem Tartrate Tablets
- Cipla Introduces Virenza Inhalation Capsules in India
- Ranbaxy Introduces Osovair in India
- GlaxoSmithKline Introduces Coreg CR(tm)
- Chugai Announces the Launch of Antiviral Agent, Copegus(r) Tablet
- Ranbaxy Unveils Generic Atorvastatin in Denmark
- Barr Unveils Generic ' PROSCAR(r)' Tablets
- Ranbaxy Introduces Niftran 100mg Capsules and Eligard 22.5mg and 45mg
- Barr Releases METAGLIP(tm) Tablets
- SkinMedica Rolls Out Single-Dosage NeoBenz(r) Micro SD for Treating Acne
- Teva Rolls Out Generic Equivalent of Wellbutrin XI(r) Tablets
- Takeda Launches Takepron (r) I.V for Injection 30mg
- Takeda Launches duetact(tm) Combination Drug in USA
- Teijin Pharma Launches Bonalon(r) Tablet for Treating Osteoporosis
11. FOCUS ON SELECT GLOBAL PLAYERS
- Abbott Laboratories (USA)
- Allergan, Inc. (USA)
- Amgen, Inc. (USA)
- AstraZeneca (UK)
- Bayer AG (Germany)
- Bristol-Myers Squibb (USA)
- Boehringer Ingelheim Group (Germany)
- Dr. Reddy' s Laboratories Ltd. (India)
- Eli Lilly and Company (USA)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Genentech, Inc. (USA)
- GlaxoSmithKline Plc (UK)
- Johnson & Johnson, Inc. (USA)
- Merck & Co. Inc. (USA)
- Merck Serono International S.A. (Switzerland)
- Mylan, Inc. (USA)
- Novartis AG (Switzerland)
- Pfizer, Inc. (USA)
- Ranbaxy Laboratories Limited (India)
- Sanofi-Aventis SA (France)
- Sanofi Pasteur (France)
- Takeda Pharmaceutical Company Limited (Japan)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Watson Pharmaceuticals, Inc. (USA)
- Wyeth (USA)
12. GLOBAL MARKET PERSPECTIVE
- Table 25: World Recent Past, Current & Future Analysis for
Prescription Drugs Market by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Billion for Years 2006 through 2015 (includes
corresponding Graph/Chart)
- Table 26: World Historic Review for Prescription Drugs Market by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and
Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion
for Years 2001 through 2005 (includes corresponding Graph/Chart)
- Table 27: World 15-year Perspective for Prescription Drugs Market by
Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years
2003, 2009 & 2015 (includes corresponding Graph/Chart)
- Table 28: World Recent Past, Current & Future Analysis for
Prescription Drugs Market by Therapeutic Class - Oncologics, Lipid Regulators,
Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics,
Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune
Agents and Others Markets Independently Analyzed with Annual Sales in US$
Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 29: World Historic Review for Prescription Drugs Market by
Therapeutic Class - Oncologics, Lipid Regulators, Respiratory Agents, Proton
Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin
II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets
Independently Analyzed with Annual Sales in US$ Billion for Years 2001 through
2005 (includes corresponding Graph/Chart)
- Table 30: World 15-year Perspective for Prescription Pharmaceuticals
Market by Therapeutic Class- Percentage Breakdown of Dollar Sales for
Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors,
Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists,
Anti-Epileptics, Autoimmune Agents and Others Markets for Years 2003, 2009
& 2015 (includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
- A. Market Analysis
- Generics in the US
- Biologics Post Highest Growth
- Leading Prescription Drugs in the US
- Table 31: Leading Prescription Drugs in the US by Value Sales (2008) in
US$ Billion - Lipitor, Nexium, Plavix, Advair Diskus, Seroquel, Singulair,
Enbrel, Neulasta, Actos and Epogen (includes corresponding Graph/Chart)
- Leading Therapeutic Classes in the US
- Table 32: US Leading Therapeutic Classes by Revenue (2006-2008):
Revenues for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors,
Seizure Disorders, Anti-Depressants, Angiotensin II Antagonists, Anteneo
Monoclonal Antibodies, Erythropoietins, Anti-Arthritics and Oral
Antiplatelets (in US$ Billion) (includes corresponding Graph/Chart)
- Table 33: US Leading Therapeutic Classes by Dispensed Prescriptions
(2006-2008): Percentage Share Breakdown for Lipid Regulators, Codiene &
Combinations, Anti- Depressants, Ace Inhibitors, Beta Blockers, Proton Pump
Inhibitors, Seizure Disorders, Synthetic Thyroid Hormones, Calcium Blockers,
Benzodiazepines, and Others (includes corresponding Graph/Chart)
- Leading Players
- Table 34: Leading Companies in the US Pharmaceutical Market (2006-2008):
Percentage Breakdown of Value Sales for Pfizer, GlaxoSmithKline, Merck &
Co., Johnson & Johnson, AstraZeneca, Amgen, Novartis, Hoffman-La Roche,
Sanofi-Aventis, Eli Lilly and Others (includes corresponding Graph/Chart)
- Table 35: US Pharmaceutical Market (2006-2008): Percentage Breakdown of
Dispensed Prescriptions for Teva Pharmaceuticals, Mylan Laboratories,
Novartis, Watson Pharma, Pfizer, Barr Laboratories, Merck & Co.,
Mallinckrodt, Apotex, Qualitest, and Others (includes corresponding
Graph/Chart)
- Prescription Drug Spending
- Table 36: Healthcare Spending in the US by Sector (2006) (includes
corresponding Graph/Chart)
- Increasing Share of Government in Prescription Drug Spending
- Table 37: US Prescription Pharmaceutical Industry (2005 and 2006):
Percentage Breakdown of Prescription Pharmaceutical Spending by Source for
Private Insurance, Medicare, Medicaid, Out-of-Pocket and Other Public
Spending (includes corresponding Graph/Chart)
- Medicare Part D
- Drug Price Regulations in the US
- Pharmaceutical Marketing - A High Investment Area in the US
- Table 38: Pharmaceutical Promotional Spending in the US by Type
(2006-2008): Professionals-Directed Promotions and Consumer-Directed
Promotions (in US$ Billion) (includes corresponding Graph/Chart)
- Major Distribution Channels
- Table 39: Major Prescription Drugs' Distribution Channels in the US by
Dispensed Prescriptions (2006-2008): Percentage Share Breakdown for Chain
Stores, Independent Stores, Food Stores, Long-term Care, and Mail Order
(includes corresponding Graph/Chart)
- Table 40: Major Prescription Drugs' Distribution Channels in the US by
Value Sakes (2006-2008): Percentage Breakdown for Distribution Channel for
Chain Stores, Mail Order, Independent Stores, Clinics, Non-government
Hospitals, Food Stores and Other Channels (includes corresponding
Graph/Chart)
- Fewer Product Launches
- Generic Penetration and PBMs Moderate Prescription Drug Price Growth
- Co-payment Differentials to Increase Generic Substitution
- High Prescription Drug Costs Drive Drug Re- Importation
- Direct-to-Consumer Advertising
- The 2006 Revision of Package Insert Format
- Other Initiatives
- Role of PBMs in the Pharmaceutical Supply Chain
- Prescription Drug Pricing in US
- Role of Mail-Order Pharmacies in Cost Containment
- Product Launches
- Strategic Corporate Developments
- Select Key Players
- B. Market Analytics
- Table 41: US Recent Past, Current & Future Analysis for Prescription
Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006
through 2015 (includes corresponding Graph/Chart)
- Table 42: US Historic Review for Prescription Drugs Market Analyzed with
Annual Sales in US$ Billion for Years 2001 through 2005 (includes
corresponding Graph/Chart)
- Table 43: US Recent Past, Current & Future Analysis for Prescription
Pharmaceuticals by Therapeutic Class - Antipsychotics, Lipid Regulators,
Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants,
Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins,
Others, Market Analyzed with Annual Sales in US$ Billion for Years 2006
through 2015 (includes corresponding Graph/Chart)
- Table 44: US Historic Review for Prescription Pharmaceuticals by
Therapeutic Class - Antipsychotics, Lipid Regulators, Proton Pump
Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II
Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, Others, Market
Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005
(includes corresponding Graph/Chart)
- Table 45: US 15-Year Perspective for Prescription Pharmaceuticals by
Therapeutic Class - Percentage Breakdown of Dollar Sales for Antipsychotics,
Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs,
Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies,
Erythropoietins, and Others for Years 2003, 2009 & 2015 (includes
corresponding Graph/Chart)
2. CANADA
- A. Market Analysis
- Current and Future Analysis
- Leading Drugs
- Table 46: Leading Prescription Drugs in Canada in Terms of Number of
Dispensed Prescriptions (2006 and 2007) in Million Scripts: Lipitor,
Synthroid, Norvasc, Asaphen, Pantoloc, Crestor, Altace, Ratio- Salbutamol
Hfa, Novo-Venlafaxine XR and Apo- Furosemide (includes corresponding
Graph/Chart)
- Major Therapeutic Classes
- Table 47: Leading Therapeutic Classes in Canada in terms of Dispensed
Prescription (2006 and 2007): Percentage Breakdown of Cardiovascular,
Antipsychotics, Gastrointestinal/Genitourinary, Lipid Regulators, Hormones,
Systemic Anti-infective, Analgesics, Diabetes Therapy, Diuretics,
Neurological Disorders and Others (includes corresponding Graph/Chart)
- Prescription Drugs Spending on the Rise
- Private Sector Insurance Continues to Gain Popularity
- Canadian Prescription Drugs Market- A Comparison with the US
- Generic Sales to Outpace Branded Drugs Sales
- Generics Market in Canada
- Generics to Offer Potential Cost Savings
- New Patented Drugs- Adding Costs but Little Value
- Two-level Drug Approval Process in Canada
- Policy Differences Affect Generic Substitution Among Provinces
- Applied and Other Research Take Major Chunk of R&D Investments in
Canada
- Table 48: Investments in Research & Development in Canada (1998,
2001, 2004 and 2007): Percentage Breakdown by Research Type- Applied
Research, Basic Research and Other Research Areas (includes corresponding
Graph/Chart)
- Product Launches
- Strategic Corporate Developments
- B. Market Analytics
- Table 49: Canadian Recent Past, Current & Future Analysis for
Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for
Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 50: Canadian Historic Review for Prescription Drugs Market
Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005
(includes corresponding Graph/Chart)
3. JAPAN
- A. Market Analysis
- Current and Future Analysis
- Generics Promotion in Japan
- Ageing Population - A Prime Target
- Competitive Landscape
- Table 51: Leading Pharmaceutical Companies in Japan (2008): Percentage
Breakdown of Revenues for Takeda Pharmaceuticals, Astellas Seiyaku, Dai-ichi
Sankyo, Mitsubishi Tanabe, Chugai Seiyaku, Pfizer, Novartis, Eisai,
GlaxoSmithKline and Otsuka Seiyaku (includes corresponding Graph/Chart)
- Table 52: Leading Prescription Drugs in Japan (2006 and 2007): Value
Sales in US$ Million for Blopress, Diovan, Norvasc, Lipitor, Aricept,
Epogin, Takepron, Leuplin, Micardis and Amlodin (includes corresponding
Graph/Chart)
- Cancer Drugs to Witness Robust Growth
- Biennial Price Reduction to Impact Markets of Key Therapeutic Classes
- Product Launches
- Strategic Corporate Developments
- Select Key Players
- B. Market Analytics
- Table 53: Japanese Recent Past, Current & Future Analysis for
Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for
Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 54: Japanese Historic Review for Prescription Drugs Market
Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005
(includes corresponding Graph/Chart)
4. EUROPE
- A. Market Analysis
- Current and Future Analysis
- Pharmaceutical Spending on the Rise
- Mounting Healthcare Bills Boost Generic Drugs Consumption
- Biogenerics Foray into Europe
- SNRIs Likely to Replace SSRIs
- Research and Development
- Table 55: European Investments in Pharma Research & Development:
2005-2007 (includes corresponding Graph/Chart)
- Europe - The Research and Production Hub for Vaccines Worldwide
- Parallel Trade in Europe
- New Rules to Offer Respite to Parallel Traders
- Manufacturers Seek Greater Control Over Supply Chain
- Pharmaceutical Industry Overview In Select Countries
- France
- Germany
- Generics
- Exports
- Production
- Prices
- New Molecular Entities
- R&D Investments
- Parallel trade
- Genetically Manufactured Drugs
- Table 56: German Genetically Manufactured Pharmaceuticals (2007):
Percentage Breakdown of Sales by Type - Vaccines, Insulins, Interferons,
Monoclonal Antibodies, Erythropoietin, and Others (includes corresponding
Graph/Chart)
- United Kingdom
- Spain
- Cost Containment Efforts
- Increased Promotion for Generics
- Re-launch of Reference Price System
- Distribution
- Italy
- Generics Gain Traction
- Sweden
- Greece
- Unique Pricing Model for Drugs
- Product Launches
- Strategic Corporate Developments
- Select Key Players
- B. Market Analytics
- Table 57: European Recent Past, Current & Future Analysis for
Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for
Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 58: European Historic Review for Prescription Drugs Market
Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005
(includes corresponding Graph/Chart)
5. ASIA-PACIFIC
- A. Market Analysis
- Current and Future Analysis
- Overview of Pharmaceutical Industries in Select Countries
- India
- Competitive Advantage
- Number of FDA Approved Plants in India Vis-a-Vis Other Countries
- Increasing Disposable Income Driving Consumption of Drugs
- Generics to Surge Growth in Exports
- Manufacturers Continue to Target Developed Markets
- India to Emerge as an Important Pharmaceutical Manufacturing Center
- Threat from Other Asian Countries
- India to Emerge as a Major Hub for Biogenerics
- Acute Therapy Class Leads the Market
- Table 59: Leading Therapeutic Categories in the Indian Pharmaceutical
Industry- Percentage Share Breakdown of Value Sales for Anti-infectives,
Gastrointestinal, Cardiovascular, Respiratory, Minerals and Vitamins,
Analgesics, Women' s Health, Central Nervous System, Dermatology, and Others
(includes corresponding Graph/Chart)
- Increase in Private Healthcare Services
- China
- Chinese Pharma Industry Remains Immune to Global Crisis, for Now
- Issues and Trends
- Pharmaceutical Firms to Play Pivotal Role in Transforming Healthcare
System
- Brand Name Drugs to Exhibit Fastest Growth, While Generics Continue to
Lead
- Generics in China
- Traditional Medicines - Substantial Share
- Table 60: Leading Medicine Types in China (2005): Percentage share for
Allopathic Medicines, Traditional Chinese Medicines (TCM), and Other Drugs
(includes corresponding Graph/Chart)
- Underserved Markets Prompt Government to Foster Development
- Domestic EPO Market Booming, Domestic Players Continue their Domination
- Chinese Antipsychotics Market to Witness Substantial Growth
- Antidepressant Drugs to Exhibit Robust Sales
- Indonesia
- Market Features
- Government-Enforced Pricing Control Over Essential Drugs
- Distribution
- Korea
- Patent Expiries of Leading Drugs in South Korea: 2008 and 2009
- Malaysia
- Foreign Investments on the Rise
- Domestic Market
- Australia
- Pharmaceutical Benefits Scheme
- Government' s Industry Development Programs
- Outlook
- Product Launches
- Strategic Corporate Developments
- Select Key Players
- B. Market Analytics
- Table 61: Asia-Pacific Recent Past, Current & Future Analysis for
Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for
Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 62: Asia-Pacific Historic Review for Prescription Drugs Market
Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005
(includes corresponding Graph/Chart)
6. LATIN AMERICA
- A. Market Analysis
- Current and Future Analysis
- Strategic Corporate Developments
- B. Market Analytics
- Table 63: Latin American Recent Past, Current & Future Analysis for
Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for
Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 64: Latin American Historic Review for Prescription Drugs Market
Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005
(includes corresponding Graph/Chart)
7. REST OF WORLD
- A. Market Analysis
- Current and Future Analysis
- Product Launches
- Strategic Corporate Developments
- B. Market Analytics
- Table 65: Rest of World Recent Past, Current & Future Analysis for
Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for
Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 66: Rest of World Historic Review for Prescription Drugs Market
Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005
(includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
|
 |
